Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium
作者: Channing J. PallerEmmanuel S. AntonarakisTomasz M. BeerHala T. BornoMaria I. CarloDaniel J. GeorgeJulie N. GraffShilpa GuptaElisabeth I. HeathCelestia S. HiganoRana R. McKayAlicia K. MorgansAkash PatnaikDaniel P. PetrylakMatthew B. RettigCharles J. RyanMary-Ellen TaplinYoung E. WhangJacob VinsonHeather H. ChengVeda N. Giri
作者单位: 1Sidney Kimmel Comprehensive Cancer Center, Department of Urology, Johns Hopkins University, Baltimore, MD
2Division of Hematology/Medical Oncology School of Medicine, Oregon Health and Science University Knight Cancer Institute, Portland, OR
3Department of Medicine, University of California San Francisco/Helen Diller Family Cancer, San Francisco, CA
4Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY
5Division of Medical Oncology, Department of Medicine and Duke Cancer Institute, Duke University Medical Center, Durham, NC
6Division of Hematology and Medical Oncology, VA Portland Health Care System/Oregon Health & Science University Knight Cancer Institute, Portland, OR
7Division of Hematology, Oncology, and Transplantation, University of Minnesota Masonic Cancer Center, Minneapolis, MN
8Karmanos Cancer Institute and Department of Oncology, Wayne State University, Detroit, MI
9Fred Hutchinson Cancer Research Center and Division of Medical Oncology, Depa
刊名: Clinical Genitourinary Cancer, 2019, Vol.17 (4), pp.275-282.e1
来源数据库: Elsevier Journal
DOI: 10.1016/j.clgc.2019.04.013
关键词: BRCADNA repairLynchPARP inhibitorsPembrolizumab
英文摘要: Abstract(#br)Background(#br)Germline genetic testing increasingly identifies advanced prostate cancer (PCa) patients who are candidates for precision therapies. The Prostate Cancer Clinical Trials Consortium (PCCTC) established the Germline Genetics Working Group to provide guidance and resources to expand effective use of germline genetic testing.(#br)Materials and Methods(#br)A 14-item questionnaire was e-mailed to academic oncologists at 43 PCCTC sites to collect information on germline genetic testing patterns, including patients considered, choice of assays, barriers slowing adoption, and actions to overcome barriers.(#br)Results(#br)Twenty-six genitourinary oncologists from 19 institutions responded. Less than 40% (10 of 26) reported referring patients to a genetics department,...
全文获取路径: Elsevier  (合作)
影响因子:1.429 (2012)

  • Cancer 巨蟹座
  • Testing 检测